EMD-15543

Single-particle
2.7 Å
EMD-15543 Deposition: 06/08/2022
Map released: 12/10/2022
Last modified: 27/03/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-15543

Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8).

EMD-15543

Single-particle
2.7 Å
EMD-15543 Deposition: 06/08/2022
Map released: 12/10/2022
Last modified: 27/03/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Human poliovirus 3
Sample: Human poliovirus 3
Fitted models: 8anw (Avg. Q-score: 0.62)

Deposition Authors: Bahar MW , Fry EE , Stuart DI
Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris .
PUBMED: 36298714
DOI: doi:10.3390/v14102159
ISSN: 1999-4915
Abstract:
Following the success of global vaccination programmes using the live-attenuated oral and inactivated poliovirus vaccines (OPV and IPV), wild poliovirus (PV) is now only endemic in Afghanistan and Pakistan. However, the continued use of these vaccines poses potential risks to the eradication of PV. The production of recombinant PV virus-like particles (VLPs), which lack the viral genome offer great potential as next-generation vaccines for the post-polio world. We have previously reported production of PV VLPs using Pichia pastoris, however, these VLPs were in the non-native conformation (C Ag), which would not produce effective protection against PV. Here, we build on this work and show that it is possible to produce wt PV-3 and thermally stabilised PV-3 (referred to as PV-3 SC8) VLPs in the native conformation (D Ag) using Pichia pastoris. We show that the PV-3 SC8 VLPs provide a much-improved D:C antigen ratio as compared to wt PV-3, whilst exhibiting greater thermostability than the current IPV vaccine. Finally, we determine the cryo-EM structure of the yeast-derived PV-3 SC8 VLPs and compare this to previously published PV-3 D Ag structures, highlighting the similarities between these recombinantly expressed VLPs and the infectious virus, further emphasising their potential as a next-generation vaccine candidate for PV.